Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M

Innoviva, Inc.

2023-Q1 EPS reported $0.42 revenue$76,372,000

Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.
GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.
Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).
Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.
FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Innoviva, Inc. reported first quarter ended March 31, 2023 results: net income Net income was $34.9 million, EPS $0.51 basic per share.

Period: first quarter ended March 31, 2023
Net income: Net income was $34.9 million
EPS: $0.51 basic per share
Result: reported results

Exact text from the filing

Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-057825

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.